Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Atropine

Related Products

Hot Products

Name

Atropine

EINECS 200-104-8
CAS No. 51-55-8 Density 1.194 g/cm3
PSA 49.77000 LogP 1.86880
Solubility 1.6g/L(18 oC) Melting Point 115-118 °C
Formula C17H23NO3 Boiling Point 429.804 °C at 760 mmHg
Molecular Weight 289.375 Flash Point 213.738 °C
Transport Information N/A Appearance white crystalline powder
Safety 25-45-36-26 Risk Codes 26/28-36/37/38-20/21/22
Molecular Structure Molecular Structure of 51-55-8 (Atropine) Hazard Symbols VeryT+,HarmfulXn
Synonyms

1aH,5aH-Tropan-3a-ol (?à)-tropate (ester) (8CI);Tropine tropate;dl-Hyoscyamine;

Article Data 35

Atropine Synthetic route

Conditions
ConditionsYield
With sodium hydroxide In water at 5℃; pH=12 - 13; Reagent/catalyst;90%
4574-60-1

atropine N-oxide hydrochloride

A

51-55-8

Atropine

B

16839-98-8

Noratropine

Conditions
ConditionsYield
Stage #1: atropine-N-oxide hydrochloride With ferrocene In isopropyl alcohol at 80℃; for 24h;
Stage #2: With sodium hydroxide In chloroform; water; isopropyl alcohol
A 21%
B 59%

3-Hydroxy-2-phenyl-propionic acid (1R,3R,5S)-8-methyl-8-oxy-8-aza-bicyclo[3.2.1]oct-3-yl ester; compound with phthalic acid

A

51-55-8

Atropine

B

16839-98-8

Noratropine

Conditions
ConditionsYield
With iron(II) sulfate In methanol at 20℃; for 6h;A 12%
B 51%
50-00-0

formaldehyd

1690-22-8

NA 181

51-55-8

Atropine

Conditions
ConditionsYield
With sodium methylate In dimethyl sulfoxide at 20℃;50%
With sodium hydroxide In water at 100℃; under 5171.62 Torr; for 0.4h; Temperature; Flow reactor;
529-64-6

Tropic acid

120-29-6

3-tropanol

51-55-8

Atropine

Conditions
ConditionsYield
With water und wiederholtes Eindampfen des entstandenen tropasauren Tropins mit verd.Salzsaeure;
16839-98-8

Noratropine

74-88-4

methyl iodide

51-55-8

Atropine

Conditions
ConditionsYield
With methanol
atropa belladonna

atropa belladonna

51-55-8

Atropine

Conditions
ConditionsYield
aus Wurzeln;
acetyl-dl-tropic acid-chloride

acetyl-dl-tropic acid-chloride

hydrochloride of tropine

hydrochloride of tropine

51-55-8

Atropine

Conditions
ConditionsYield
Man laesst das entstandene salzsaure Acetylatropin in waessr.Loesung bei Zimmertemperatur stehen;
Man laesst das entstandene salzsaure Acetylatropin in waessr.Loesung bei Zimmertemperatur stehen;
hyoscyamine

hyoscyamine

51-55-8

Atropine

Conditions
ConditionsYield
at 110 - 120℃;
With sodium hydroxide; ethanol
With sodium hydroxide; ethanol; carbon dioxide at 5℃;
at 120 - 130℃;
With methanol; phenol
529-64-6

Tropic acid

tropine sulfate

tropine sulfate

51-55-8

Atropine

Conditions
ConditionsYield
With isopropyl alcohol

Atropine History

 Atropine (CAS NO.51-55-8) extracts from the Egyptian henbane were used by Cleopatra in the last century B.C. to dilate her pupils, in the hope that she would appear more alluring. The mydriatic effects of atropine were studied among others by the German chemist Friedrich Ferdinand Runge (1795–1867). In 1831, the pharmacist Mein succeeded the pure crystalline isolation of atropine. Its substance was first synthesized in 1901 by German chemist Richard Willstätter. The mydriatic effects of atropine were studied among others by the German chemist Friedrich Ferdinand Runge (1795–1867).

Atropine Consensus Reports

Reported in EPA TSCA Inventory.

Atropine Specification

The Atropine, with the CAS registry number 51-55-8, is also known as beta-Phenyl-gamma-oxypropionsaeure-tropyl-ester. It belongs to the product categories of Pharmaceutical; Alkaloids; Biochemistry; Tropane Alkaloids. Its EINECS registry number is 200-104-8. This chemical's molecular formula is C17H23NO3 and molecular weight is 289.37. Its IUPAC name is called [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate. This chemical's classification codes are Adjuvants, anesthesia; Anti-Asthmatic Agents; Anti-arrhythmia agents; Anticholinergic; Autonomic Agents; Bronchodilator agents; Cardiovascular Agents; Central Nervous System Agents; Cholinergic Agents; Cholinergic Antagonists; Drug / Therapeutic Agent; Human Data; Muscarinic antagonists; Mutation data; Mydriatics; Neurotransmitter Agents; Parasympatholytics; Peripheral Nervous System Agents; Reproductive Effect; Respiratory System Agents.

Physical properties of Atropine: (1)ACD/LogP: 1.38; (2)ACD/LogD (pH 5.5): -2; (3)ACD/LogD (pH 7.4): -1; (4)ACD/BCF (pH 5.5): 1; (5)ACD/BCF (pH 7.4): 1; (6)ACD/KOC (pH 5.5): 1; (7)ACD/KOC (pH 7.4): 1; (8)#H bond acceptors: 4; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 6; (11)Index of Refraction: 1.581; (12)Molar Refractivity: 80.788 cm3; (13)Molar Volume: 242.421 cm3; (14)Surface Tension: 50.459 dyne/cm; (15)Density: 1.194 g/cm3; (16)Flash Point: 213.738 °C; (17)Enthalpy of Vaporization: 72.224 kJ/mol; (18)Boiling Point: 429.804 °C at 760 mmHg; (19)Vapour Pressure: 0 mmHg at 25°C.

Preparation: Atropine is a tropane alkaloid extracted from deadly nightshade (Atropa belladonna), jimsonweed (Datura stramonium), mandrake (Mandragora officinarum) and other plants of the family Solanaceae. It is a secondary metabolite of these plants and serves as a drug with a wide variety of effects. Atropine can be synthesized by the reaction of tropine with tropic acid in the presence of hydrochloric acid.

Atropine increases firing of the sinoatrial node (SA) and conduction through the atrioventricular node (AV) of the heart, opposes the actions of the vagus nerve, blocks acetylcholine receptor sites, and decreases bronchial secretions. In general, atropine lowers the parasympathetic activity of all muscles and glands regulated by the parasympathetic nervous system. Topical atropine is used as a cycloplegic, to temporarily paralyze the accommodation reflex, and as a mydriatic, to dilate the pupils. Injections of atropine are used in the treatment of bradycardia (an extremely low heart rate), asystole and pulseless electrical activity (PEA) in cardiac arrest. Atropine is also useful in treating second-degree heart block Mobitz Type 1 (Wenckebach block), and also third-degree heart block with a high Purkinje or AV-nodal escape rhythm.

When you are using this chemical, please be cautious about it as the following:
This chemical that at very low levels can cause damage to health. It may cause damage to health. It is harmful by inhalation, in contact with skin and if swallowed. In addition, it is irritating to eyes, respiratory system and skin. In case of contact with eyes, you should rinse immediately with plenty of water and seek medical advice. Whenever you will contact it, please wear suitable protective clothing.

You can still convert the following datas into molecular structure:
(1)Canonical SMILES: CN1C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
(2)Isomeric SMILES: CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3
(3)InChI: InChI=1S/C17H23NO3/c1-18-13-7-8-14(18)10-15(9-13)21-17(20)16(11-19)12-5-3-2-4-6-12/h2-6,13-16,19H,7-11H2,1H3/t13-,14+,15?,16?
(4)InChIKey: RKUNBYITZUJHSG-PJPHBNEVSA-N

The toxicity data is as follows:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
cat LDLo intravenous 70mg/kg (70mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 483, 1948.
cat LDLo subcutaneous 130mg/kg (130mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 1, 1937.
dog LDLo intravenous 50mg/kg (50mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

BEHAVIORAL: MUSCLE WEAKNESS

GASTROINTESTINAL: NAUSEA OR VOMITING
Proceedings of the Society for Experimental Biology and Medicine. Vol. 40, Pg. 244, 1939.
dog LDLo unreported 60mg/kg (60mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 513, 1948.
frog LDLo intramuscular 750mg/kg (750mg/kg) BEHAVIORAL: EXCITEMENT

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Proceedings of the Society for Experimental Biology and Medicine. Vol. 40, Pg. 244, 1939.
frog LDLo subcutaneous 1gm/kg (1000mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1311, 1935.
guinea pig LD50 intraperitoneal 400mg/kg (400mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 105, Pg. 166, 1952.
guinea pig LD50 oral 1100mg/kg (1100mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 105, Pg. 166, 1952.
human TDLo intramuscular 1ug/kg (0.001mg/kg) SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE "Possible Long-Term Health Effects of Short-Term Exposure to Chemical Agents," National Research Council, 3 vols., Washington, DC, National Academy Press, 1982-85Vol. 1, Pg. L1, 1982.
human TDLo oral 33ug/kg (0.033mg/kg) SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE

BEHAVIORAL: MUSCLE WEAKNESS
Journal of Toxicology, Clinical Toxicology. Vol. 22, Pg. 581, 1984/1985.
man LDLo unreported 143ug/kg (0.143mg/kg)   "Structure et Activite Pharmacodyanmique des Medicaments du Systeme Nerveux Vegetatif," Bovet, D., and F. Bovet-Nitti, New York, S. Karger, 1948Vol. -, Pg. 482, 1948.
man TDLo intramuscular 175ug/kg (0.175mg/kg) BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS" Federation Proceedings, Federation of American Societies for Experimental Biology. Vol. 32, Pg. 250, 1973.
man TDLo intravenous 14ug/kg (0.014mg/kg) BEHAVIORAL: HEADACHE

VASCULAR: BP ELEVATION NOT CHARACTERIZED IN AUTONOMIC SECTION
Annals of Internal Medicine. Vol. 101, Pg. 720, 1984.
mouse LD50 intradermal 550mg/kg (550mg/kg) BEHAVIORAL: EXCITEMENT

BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938.
mouse LD50 intraperitoneal 30mg/kg (30mg/kg)   Journal of Medicinal Chemistry. Vol. 31, Pg. 683, 1988.
mouse LD50 intravenous 30mg/kg (30mg/kg)   Journal of Medicinal Chemistry. Vol. 28, Pg. 1760, 1985.
mouse LD50 oral 75mg/kg (75mg/kg) BEHAVIORAL: EXCITEMENT

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: ATAXIA
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938.
mouse LD50 subcutaneous 428mg/kg (428mg/kg)   Zhongcaoyao. Chinese Traditional and Herbal Medicine. Vol. 11, Pg. 457, 1980.
rabbit LD50 intradermal 500mg/kg (500mg/kg) BEHAVIORAL: EXCITEMENT

BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938.
rabbit LD50 intravenous 50mg/kg (50mg/kg) BEHAVIORAL: EXCITEMENT

BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938.
rabbit LD50 oral 600mg/kg (600mg/kg) BEHAVIORAL: EXCITEMENT

BEHAVIORAL: ATAXIA

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Archives Internationales de Pharmacodynamie et de Therapie. Vol. 59, Pg. 149, 1938.
rabbit LDLo intraperitoneal 350ug/kg (0.35mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION

CARDIAC: PULSE RATE
Journal of Pharmacology and Experimental Therapeutics. Vol. 60, Pg. 14, 1937.
rabbit LDLo subcutaneous 500mg/kg (500mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1311, 1935.
rat LD50 intramuscular 920mg/kg (920mg/kg)   Drug and Chemical Toxicology. Vol. 1, Pg. 355, 1978.
rat LD50 intraperitoneal 280mg/kg (280mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 105, Pg. 166, 1952.
rat LD50 intravenous 73mg/kg (73mg/kg)   Schweizerische Medizinische Wochenschrift. Vol. 76, Pg. 1282, 1946.
rat LD50 oral 500mg/kg (500mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 155, Pg. 393, 1965.
rat LD50 subcutaneous 250mg/kg (250mg/kg)   Archives Internationales de Pharmacodynamie et de Therapie. Vol. 68, Pg. 339, 1942.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 51-55-8